PCN120 - The Cost-Effectiveness of Nivolumab for The Treatment of People with Relapsed or Refractory Classical Hodgkin Lymphoma Following Autologous Stem Cell Transplant and Brentuximab Vedotin
- Resource Type
- Abstract
- Source
- In
Value in Health October-November 2017 20(9):A433-A433 - Subject
- Language
- ISSN
- 1098-3015